Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Celecoxib and cardiovascular risks.

James M Brophy1

  • 1McGill University Health Centre, Division of Cardiology, Royal Victoria Hospital, Montréal, Québec, H3A 1A1, Canada. james.brophy@mcgill.ca

Expert Opinion on Drug Safety
|November 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Cluster Randomized Trial of an mHealth Intervention for Adolescents With Congenital Heart Disease: Rationale and Design of the READYorNot CHD Study.

CJC pediatric and congenital heart disease·2026
Same author

Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.

JAMA network open·2026
Same author

Causality in Observational Cardiology: "Chapeau" to a Bias Analysis Approach.

Circulation. Population health and outcomes·2026
Same author

Extended thrombolysis in acute ischemic stroke: A Bayesian meta-analysis and umbrella review.

The American journal of emergency medicine·2026
Same author

Aortic Valve Replacement for Severe Asymptomatic Aortic Stenosis-A Systemic Review and Bayesian Meta-analysis.

The Canadian journal of cardiology·2025
Same author

Sex Differences in the Impact of Exercise Volume on Subclinical Coronary Atherosclerosis: A Meta-Analysis.

JACC. Advances·2025
Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026
Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026
Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026
Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026
Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026
Same journal

Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury.

Expert opinion on drug safety·2026
See all related articles

COX-2 inhibitors show varied cardiovascular risks. While some drugs like rofecoxib pose risks, celecoxib

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Safety

Background:

  • Cyclooxygenase-2 (COX-2) inhibitors were developed to reduce pain and inflammation.
  • Initial hypotheses suggested selective COX-2 inhibition would avoid gastrointestinal and bleeding risks associated with traditional NSAIDs.

Purpose of the Study:

  • To systematically review the evidence linking COX-2 inhibitors to cardiovascular risk.
  • To evaluate whether cardiovascular toxicity is a class effect of all COX-2 inhibitors.

Main Methods:

  • Systematic review of scientific literature.
  • Analysis of evidence regarding cardiovascular risk associated with specific COX-2 inhibitors (rofecoxib, valdecoxib, celecoxib).

Main Results:

Related Experiment Videos

  • Rofecoxib and valdecoxib were withdrawn from the market due to increased cardiovascular risk.
  • Evidence for celecoxib's cardiovascular risk is equivocal, with totality of evidence suggesting a small risk comparable to traditional NSAIDs.
  • Cardiovascular risks appear heterogeneous, influenced by drug, dose, and patient factors.

    • Conclusions:

    • Cardiovascular risks associated with COX-2 inhibitors are not uniform across the drug class.
    • Further research is needed to understand modifying factors like dose, concomitant medications, and patient-specific profiles.
    • The cardiovascular risks of COX-2 inhibitors are influenced by individual drug, dosage, and patient characteristics.